FDA inspection

Cephazone Pharma, LLC: FDA inspection ending Sep 19, 2005

FDA inspection 396542 · Voluntary Action Indicated (VAI) · Pomona, CA

Key facts

Inspection ID 396542
Firm Cephazone Pharma, LLC
FEI number 3003701857
Address 250 E Bonita Ave
City Pomona
State CA
ZIP 91767-1924
Fiscal year 2005
Inspection end date Sep 19, 2005
Classification Voluntary Action Indicated (VAI)
Project area Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation
Product type Drugs

At a glance

  • None Citations
  • 1–9 Posted citations
  • No Warning letter followed
  • Yes Form FDA 483 issued
  • No Establishment inspection report (EIR) exists
  • 10–99 Inspections at this FEI

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About FDA inspections

FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.

Source: U.S. Food and Drug Administration (FDA), inspection classification data

Browse all FDA inspections